Drug Eluting Balloons Catheters Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The drug eluting balloons catheters market size has grown rapidly in recent years. It will grow from $1.43 billion in 2024 to $1.66 billion in 2025 at a compound annual growth rate (CAGR) of 16%. The growth in the historic period can be attributed to increasing respiratory disorders, advantages over traditional inhalers, patient preference for dpis, government initiatives for respiratory health, strategic collaborations and partnerships, advancements in drug formulations, rising geriatric population.

The drug eluting balloons catheters market size is expected to see rapid growth in the next few years. It will grow to $2.61 billion in 2029 at a compound annual growth rate (CAGR) of 12%. The growth in the forecast period can be attributed to continued growth in respiratory disorders, expanding geriatric population, increasing awareness and education, market expansion in emerging economies, customized drug formulations, regulatory support and compliance, innovations in packaging and design. Major trends in the forecast period include smart inhalers and connectivity, shift towards breath-actuated inhalers, focus on pediatric and geriatric patient needs, biologics delivery, environmentally friendly inhaler designs.

The increasing prevalence of peripheral and cardiovascular diseases is anticipated to drive the growth of the drug-eluting balloon catheter market in the future. Cardiovascular diseases (CVDs) encompass a range of conditions affecting the heart and circulatory system, while peripheral artery disease (PAD) specifically involves the narrowing of arteries that diminishes blood flow mainly to the arms or legs. Drug-eluting balloon catheters are utilized in the treatment of coronary artery disease (CAD); they feature a semi-compliant angioplasty balloon coated with an anti-proliferative agent that exerts an anti-restenotic effect upon entering the vessel. For example, in May 2024, the Centers for Disease Control and Prevention (CDC), a U.S.-based government agency, reported that in 2022, heart disease was responsible for 702,880 deaths, representing 1 in every 5 fatalities. Annually, around 805,000 individuals in the United States suffer a heart attack, with approximately 605,000 being their first heart attack and 200,000 occurring in those who have previously experienced one. Thus, the rising prevalence of peripheral and cardiovascular diseases is propelling the drug-eluting balloon catheter market.

The increasing demand for minimally invasive procedures is expected to further propel the growth of the drug-eluting balloon catheter market. Minimally invasive procedures involve surgical techniques with small incisions, resulting in reduced healing time, less pain, and lower infection risks. Drug-eluting balloons are crucial in these procedures, delivering medication directly to the treatment area to prevent restenosis and enhance the effectiveness of vascular interventions. For instance, Intuitive Surgical Inc. reported an 18% increase in surgical procedures using Vinci surgical systems from 1,594,000 in 2021 to 1,875,000 in 2022. Additionally, the American Society of Plastic Surgeons noted a rise in cosmetic minimally invasive procedures in the US to 23,672,269 in 2022. Therefore, the increasing demand for minimally invasive procedures is driving the growth of the drug-eluting balloon catheter market.

Key players in the drug-eluting balloon catheter market are intensifying their efforts to develop next-generation products with advanced technologies to secure a competitive advantage. For instance, in March 2024, Boston Scientific Corporation, a U.S.-based biomedical and biotechnology engineering firm, announced it had received U.S. Food and Drug Administration (FDA) approval for the AGENT Drug-Coated Balloon (DCB). This product is the first drug-coated coronary balloon available in the U.S. specifically designed for treating in-stent restenosis (ISR), a condition where plaque or scar tissue obstructs a previously stented vessel. The AGENT DCB features a paclitaxel coating that provides a therapeutic dose to the vessel wall, effectively reducing ISR recurrence without the need for additional stents or radiation. Clinical trials demonstrated a 49% reduction in the risk of heart attack at the target site, along with low rates of adverse events.

In June 2023, Translumina Therapeutics Company acquired Blue Medical Devices BV for an undisclosed amount. This strategic acquisition aimed to integrate Blue Medical's unique drug application technology into Translumina's product lines, expanding offerings in neurovascular and peripheral interventions and enhancing drug coating capabilities. Blue Medical Devices BV is a Netherlands-based medical device company specializing in producing drug-eluting balloon catheters.

Major companies operating in the drug eluting balloons catheters market report are Abbott Laboratories, Medtronic PLC, Becton Dickinson and Company, Koninklijke Philips NV, Boston Scientific Corporation, B Braun Melsungen Aktiengesellschaft, Terumo Corporation, Cook Medical LLC, Lepu Medical Technology Co. Ltd., Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corporation, BIOTRONIK SE & Co. KG, Acotec Scientific Co. Ltd., Cordis Corporation, Biosensors International Group Ltd., Zylox-Tonbridge Medical Technology Co. Ltd., Mermaid Medical AS, Hexacath Limited, Zhejiang Barty Medical Technology Co. Ltd., Cardionovum GmbH, Nano Therapeutics Pvt. Ltd., Tokai Medical Products Inc., Opto Circuits Limited, Acrostak (Schweiz) AG, Machine Solutions Inc., Concept Medical Inc., Aachen Resonance GmbH, AR Baltic Medical UAB.

North America was the largest region in the drug eluting balloons catheters market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug eluting balloons catheters market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the drug-eluting balloon catheter market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The drug-eluting balloon catheter market consists of sales of everolimus and stellarex. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

A drug-eluting balloon catheter is a medical device utilized in the treatment of coronary artery disease through percutaneous coronary intervention (PCI). It is a semi-compliant angioplasty balloon that is coated with an anti-proliferative drug. During inflation, the drug is released into the vessel wall, aiming to prevent restenosis and reduce the risk of late thrombosis without the need for implanting a permanent foreign object.

The main types of drug-eluting balloon catheters include those designed for coronary artery disease and peripheral vascular disease. Coronary artery disease drug-eluting balloon catheters deliver antiproliferative drugs directly to the vessel wall using a lipophilic matrix, eliminating the need for a permanent structure such as a metal prosthesis or persistent polymer. Various drugs such as paclitaxel and sirolimus are used, and the catheters are made from raw materials such as nylon, polyurethane, and others. They find applications in hospitals, clinics, ambulatory surgical centers, and catheterization laboratories.

The drug eluting balloons catherers market research report is one of a series of new reports that provides drug eluting balloons catherers market statistics, including drug eluting balloons catherers industry global market size, regional shares, competitors with a drug eluting balloons catherers market share, detailed drug eluting balloons catherers market segments, market trends and opportunities, and any further data you may need to thrive in the drug eluting balloons catherers industry. This drug eluting balloons catherers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.